1
|
Sang H, Li L, Zhao Q, Liu Y, Hu J, Niu P, Hao Z, Chai K. The regulatory process and practical significance of non-coding RNA in the dissemination of prostate cancer to the skeletal system. Front Oncol 2024; 14:1358422. [PMID: 38577343 PMCID: PMC10991771 DOI: 10.3389/fonc.2024.1358422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2023] [Accepted: 03/12/2024] [Indexed: 04/06/2024] Open
Abstract
Prostate cancer is a major contributor to male cancer-related mortality globally. It has a particular affinity for the skeletal system with metastasis to bones seriously impacting prognosis. The identification of prostate cancer biomarkers can significantly enhance diagnosis and patient monitoring. Research has found that cancer and metastases exhibit abnormal expression of numerous non-coding RNA. Some of these RNA facilitate prostate cancer bone metastasis by activating downstream signaling pathways, while others inhibit this process. Elucidating the functional processes of non-coding RNA in prostate cancer bone metastasis will likely lead to innovative treatment strategies for this malignant condition. In this review, the mechanistic role of the various RNA in prostate cancer is examined. Our goal is to provide a new avenue of approach to the diagnosis and treatment of bone metastasis in this cancer.
Collapse
Affiliation(s)
- Hui Sang
- Department of Urology, The Third Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Baiyin, China
| | - Luxi Li
- Department of Urology, The Third Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Baiyin, China
| | - Qiang Zhao
- Department of Urology, The Third Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Baiyin, China
| | - Yulin Liu
- Department of Urology, The Third Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Baiyin, China
| | - Jinbo Hu
- Department of Urology, The Third Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Baiyin, China
| | - Peng Niu
- Department of Urology, The Third Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Baiyin, China
| | - Zhenming Hao
- Department of Urology, The Third Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Baiyin, China
| | - Keqiang Chai
- Department of Urology, The Third Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Baiyin, China
| |
Collapse
|
2
|
Asante DM, Sreekumar A, Nathani S, Lee TJ, Sharma A, Patel N, Simmons MN, Saini S. miR-410 Is a Key Regulator of Epithelial-to-Mesenchymal Transition with Biphasic Role in Prostate Cancer. Cancers (Basel) 2023; 16:48. [PMID: 38201476 PMCID: PMC10777946 DOI: 10.3390/cancers16010048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2023] [Revised: 12/04/2023] [Accepted: 12/11/2023] [Indexed: 01/12/2024] Open
Abstract
The molecular basis of prostate cancer (PCa) progression from the primary disease to metastatic castration-resistant prostate cancer (CRPC) followed by therapy-induced neuroendocrine prostate cancer is not fully understood. In this study, we elucidate the role of miR-410, a little-studied microRNA located on chromosome 14q32.31 within the DLK1-DIO3 cluster, in PCa. miR-410 expression analyses in primary and metastatic PCa tissues and cell lines show that its levels are decreased in initial stages and increased in advanced PCa. Functional studies were performed in a series of PCa cell lines. In LNCaP cells, miR-410 overexpression led to decreases in cellular viability, proliferation, invasiveness, and migration. On the other hand, miR-410 overexpression in PC3 and C42B cells led to increased viability, proliferation, and invasiveness. Our data suggest that miR-410 represses epithelial-to-mesenchymal transition (EMT) in LNCaP cells by directly repressing SNAIL. However, it promotes EMT and upregulates PI3K/Akt signaling in PC3 and C42B cells. In vivo studies with PC3 xenografts support an oncogenic role of miR-410. These data suggest that miR-410 acts as a tumor suppressor in the initial stages of PCa and play an oncogenic role in advanced PCa. Our findings have important implications in understanding the molecular basis of PCa progression with potential translational implications.
Collapse
Affiliation(s)
- Diana M. Asante
- Department of Biochemistry and Molecular Biology, Augusta University, Augusta, GA 30912, USA; (D.M.A.); (A.S.); (S.N.)
| | - Amritha Sreekumar
- Department of Biochemistry and Molecular Biology, Augusta University, Augusta, GA 30912, USA; (D.M.A.); (A.S.); (S.N.)
| | - Sandip Nathani
- Department of Biochemistry and Molecular Biology, Augusta University, Augusta, GA 30912, USA; (D.M.A.); (A.S.); (S.N.)
| | - Tae Jin Lee
- Department of Center for Biotechnology and Genomic Medicine, Augusta University, Augusta, GA 30912, USA; (T.J.L.); (A.S.)
| | - Ashok Sharma
- Department of Center for Biotechnology and Genomic Medicine, Augusta University, Augusta, GA 30912, USA; (T.J.L.); (A.S.)
| | - Nikhil Patel
- Department of Pathology, Augusta University, Augusta, GA 30912, USA;
| | | | - Sharanjot Saini
- Department of Biochemistry and Molecular Biology, Augusta University, Augusta, GA 30912, USA; (D.M.A.); (A.S.); (S.N.)
| |
Collapse
|
3
|
Liao S, Fang X, Zhou K, Zhao T, Ji L, Zhang W, Zhong X, Feng F, Lv J, Kang Y, Zhu D. LINC00482 sponged miR-2467-3p to promote bone metastasis of prostate cancer through activating Wnt/β-catenin signaling pathway. J Bone Oncol 2023; 41:100494. [PMID: 37575527 PMCID: PMC10413070 DOI: 10.1016/j.jbo.2023.100494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2022] [Revised: 06/30/2023] [Accepted: 07/18/2023] [Indexed: 08/15/2023] Open
Abstract
This study was designed to investigate the biological functions of LINC00482 in prostate cancer (PCa) with bone metastasis. TCGA dataset of PCa was applied for LINC00482 expression analysis and real time PCR was used to verify the expression level of LINC00482 in PCa tissues as well as PCa bone metastatic tissues. To detect the biological functions of LINC00482 in vitro, various assays were used including CCK-8, EdU, colony formation and transwell assays. The biological functions of LINC00482 were also identified in vivo by inoculating PCa cells into the left cardiac ventricle of mice, followed by evaluating the osteolytic lesions and osteolytic score. In addition, Starbase and Lncbase databases were applied for predicting the potential target miRNA of LINC00482, while TargetScan and Starbase databases were used for predicting the potential target of miRNA. The luciferase reporter assay was utilized to determine the interactions among these molecules and western blotting was employed to verified the targeted proteins. Results showed that high expression level of LINC00482 was observed in bone metastatic PCa tissues and associated with PCa progression. Silencing of LINC00482 inhibited cell proliferation, migration and invasion in PCa. Furthermore, LINC00482 was proved to act as a competing endogenous RNA by sponging miR-2467-3p to activate Wnt/β-catenin signaling pathway, which may be a promising therapeutic target for PCa with bone metastasis.
Collapse
Affiliation(s)
- Shiyao Liao
- Department of Orthopedics, Zhejiang Provincial People’s Hospital, Shangtang Road 158#, Hangzhou, Zhejiang, China
- Hangzhou Medical College People’s Hospital, Hangzhou, Zhejiang, China
| | - Xuemei Fang
- Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China
- State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China
| | - Kai Zhou
- The First Affiliated Hospital of Wenzhou Medical University, Nanbaixiang Street, Ouhai District, Wenzhou City, Zhejiang, China
| | - Tingxiao Zhao
- Department of Orthopedics, Zhejiang Provincial People’s Hospital, Shangtang Road 158#, Hangzhou, Zhejiang, China
- Hangzhou Medical College People’s Hospital, Hangzhou, Zhejiang, China
| | - Lichen Ji
- Department of Orthopedics, Zhejiang Provincial People’s Hospital, Shangtang Road 158#, Hangzhou, Zhejiang, China
- The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, China
| | - Wei Zhang
- Department of Orthopedics, Zhejiang Provincial People’s Hospital, Shangtang Road 158#, Hangzhou, Zhejiang, China
- Qingdao University, Qingdao, China
| | - Xugang Zhong
- Department of Orthopedics, Zhejiang Provincial People’s Hospital, Shangtang Road 158#, Hangzhou, Zhejiang, China
- Qingdao University, Qingdao, China
| | - Fabo Feng
- Department of Orthopedics, Zhejiang Provincial People’s Hospital, Shangtang Road 158#, Hangzhou, Zhejiang, China
- Hangzhou Medical College People’s Hospital, Hangzhou, Zhejiang, China
| | - Jun Lv
- Department of Orthopedics, Zhejiang Provincial People’s Hospital, Shangtang Road 158#, Hangzhou, Zhejiang, China
- Hangzhou Medical College People’s Hospital, Hangzhou, Zhejiang, China
| | - Yao Kang
- Department of Orthopedics, Zhejiang Provincial People’s Hospital, Shangtang Road 158#, Hangzhou, Zhejiang, China
- Hangzhou Medical College People’s Hospital, Hangzhou, Zhejiang, China
| | - Danjie Zhu
- Department of Orthopedics, Zhejiang Provincial People’s Hospital, Shangtang Road 158#, Hangzhou, Zhejiang, China
- Hangzhou Medical College People’s Hospital, Hangzhou, Zhejiang, China
| |
Collapse
|
4
|
Kang Z, Luo Y, Xiao E, Li Q, Wang L. CD151 and prostate cancer progression: A review of current literature. Asia Pac J Clin Oncol 2022. [DOI: 10.1111/ajco.13890] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2022] [Revised: 09/27/2022] [Accepted: 10/03/2022] [Indexed: 12/05/2022]
Affiliation(s)
- Zhen Kang
- Department of RadiologyTongji HospitalTongji Medical CollegeHuazhong University of Science and Technology WuhanChina
| | - Yanping Luo
- Department of Immunology School of Basic Medical Sciences Lanzhou University Lanzhou China
| | - Enhua Xiao
- Department of Radiology The Second Xiangya Hospital Central South University Changsha China
| | - Qiubai Li
- Department of Radiology University Hospitals Cleveland Medical Center Cleveland Ohio USA
| | - Liang Wang
- Department of RadiologyTongji HospitalTongji Medical CollegeHuazhong University of Science and Technology WuhanChina
| |
Collapse
|
5
|
Single-cell sequencing reveals MYC targeting gene MAD2L1 is associated with prostate cancer bone metastasis tumor dormancy. BMC Urol 2022; 22:37. [PMID: 35305591 PMCID: PMC8934453 DOI: 10.1186/s12894-022-00991-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2021] [Accepted: 03/09/2022] [Indexed: 12/13/2022] Open
Abstract
Abstract
Background
Among malignant tumors, bone metastasis is frequently associated with prostate cancer which is seen in about 80% of patients. During cancer treatments, some tumor cells switch to a "dormant mode" to help tumor cells avoid attack from the immune system and anti-tumor therapies. In this dormant mode, tumor cells can be resuscitated, causing cancer to reoccur. The generally accepted explanation for this phenomenon is that the tumor cells have spread to the bone marrow before treatment and are dormant in the bone marrow. However, the key mechanism for inducing and maintaining the dormancy of these prostate cancer disseminated tumor cells in the bone marrow is still unclear. Therefore, studying the dormancy mechanism of tumor cells in bone metastasis is of great significance for the treatment and the prevention of recurrence of prostate cancer.
Methods
We obtained single-cell RNA-seq data of tumors from mouse models of prostate cancer bone metastasis mouse model numbered (GSE147150) from the GEO database, and obtained RNA-seq expression data and clinical information from The Cancer Genome Atlas Program (TCGA) of prostate cancer patients from the USCS Xena database. Screening of differential genes and annotation of GO functions were performed separately. Subsequently, the screened differential genes were compared and analyzed with 50 classic Hallmark signaling pathways, and the prognosis analysis of prostate cancer patients in TCGA data was performed to discover the key genes of the dormant mechanism of tumor cells in bone metastasis, and obtain new biomarkers that can be used to predict the prognosis of patients.
Results
A total of 378 differentially expressed genes were screened, of which 293 were significantly up-regulated and 85 were significantly down-regulated. Among them, the up-regulated genes were mainly related to the immune response, and the down-regulated genes were mainly related to the cell cycle. Through GSVA (Gene set variation analysis), it is found that there are differences in a total of 3 signal pathways: COMPLEMENT, MYC_TARGETS_V1 and MYC_TARGETS_V2. By comparing and analyzing the significantly down-regulated genes in dormant tumor cells with MYC_TARGETS_V1, MYC_TARGETS_V2, three significantly down-regulated genes were obtained: Ccna2, Mad2L1 and Plk1.
Conclusion
In summary, our findings indicate that the MYC targeting gene Mad2L1 is potentially related to the dormancy mechanism of prostate cancer. At the same time, Mad2L1, a gene associated with dormant prostate cancer cells, may be used as a biomarker for prognostic survival.
Collapse
|
6
|
Zhang G, Liu Y, Yang J, Wang H, Xing Z. Inhibition of circ_0081234 reduces prostate cancer tumor growth and metastasis via miR-1/MAP3K1 axis. J Gene Med 2021; 24:e3376. [PMID: 34191363 DOI: 10.1002/jgm.3376] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2021] [Revised: 06/25/2021] [Accepted: 06/28/2021] [Indexed: 12/24/2022] Open
Abstract
INTRODUCTION Circular RNAs (circRNAs) are crucial regulators in tumor occurrence and progression, and circRNAs are enriched and stable in exosomes. This study aimed to explore the role and potential mechanism of cancer-derived exosomal circ_0081234 in prostate cancer (PCa). METHODS Exosomes were extracted using the ExoQuick Precipitation Kit. The levels of circ_0081234, miR-1 and mitogen-activated protein kinase kinase kinase 1 (MAP 3K1) were examined using qRT-PCR or western blot. Cell migration and invasion were evaluated via transwell assay. The protein levels of N-cadherin, Vimentin and E-cadherin were detected by western blot. The interaction between miR-1 and circ_0081234 or MAP 3K1 was verified via dual-luciferase reporter assay and RNA pull-down assay. RESULTS Circ_0081234 level was increased in PC a tissues with spinal metastasis (SM) in comparison to primary PCa tissues without SM. Exosomal circ_0081234 promoted the migration, invasion and epithelial-mesenchymal transition (EMT) of PCa cells. Knockdown of circ_0081234 blocked PCa cell progression via regulating miR-1. In addition, miR-1 overexpression suppressed PCa cell progression by repressing MAP 3K1. Moreover, circ_0081234 increased MAP 3K1 level via sponging miR-1. Depletion of circ_0081234 inhibited tumor growth in vivo. CONCLUSION Exosomal circ_0081234 promoted migration, invasion and EMT of PCa cells by regulating the miR-1/MAP 3K1 axis.
Collapse
Affiliation(s)
- Guangyao Zhang
- Department of General Surgery, Huiji Hospital of the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
| | - Yibin Liu
- Department of Emergency Surgery, Huiji Hospital of the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
| | - Jianhui Yang
- Department of General Surgery, Huiji Hospital of the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
| | - Haiming Wang
- Department of General Surgery, Huiji Hospital of the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
| | - Zhengwei Xing
- Medical office, Huiji Hospital of the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
| |
Collapse
|
7
|
Karkhane M, Lashgarian HE, Hormozi M, Fallahi S, Cheraghipour K, Marzban A. Oncogenesis and Tumor Inhibition by MicroRNAs and its Potential Therapeutic Applications: A Systematic Review. Microrna 2021; 9:198-215. [PMID: 31686643 DOI: 10.2174/2211536608666191104103834] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2019] [Revised: 08/01/2019] [Accepted: 10/21/2019] [Indexed: 12/12/2022]
Abstract
MicroRNAs appear as small molecule modifiers, which improve many new findings and mechanical illustrations for critically important biological phenomena and pathologic events. The best-characterized non-coding RNA family consists of about 2600 human microRNAs. Rich evidence has revealed their crucial importance in maintaining normal development, differentiation, growth control, aging, modulation of cell survival or apoptosis, as well as migration and metastasis as microRNAs dysregulation leads to cancer incidence and progression. By far, microRNAs have recently emerged as attractive targets for therapeutic intervention. The rationale for developing microRNA therapeutics is based on the premise that aberrantly expressed microRNAs play a significant role in the emergence of a variety of human diseases ranging from cardiovascular defects to cancer, and that repairing these microRNA deficiencies by either antagonizing or restoring microRNA function may yield a therapeutic benefit. Although microRNA antagonists are conceptually similar to other inhibitory therapies, improving the performance of microRNAs by microRNA replacement or inhibition that is a less well- described attitude. In this assay, we have condensed the last global knowledge and concepts regarding the involvement of microRNAs in cancer emergence, which has been achieved from the previous studies, consisting of the regulation of key cancer-related pathways, such as cell cycle control and the DNA damage response and the disruption of profile expression in human cancer. Here, we have reviewed the special characteristics of microRNA replacement and inhibition therapies and discussed explorations linked with the delivery of microRNA mimics in turmeric cells. Besides, the achievement of biomarkers based on microRNAs in clinics is considered as novel non-invasive biomarkers in diagnostic and prognostic assessments.
Collapse
Affiliation(s)
- Maryam Karkhane
- Department of Medical Biotechnology, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
| | - Hamed Esmaeil Lashgarian
- Department of Medical Biotechnology, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
| | - Maryam Hormozi
- Department of Biochemistry, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
| | - Shirzad Fallahi
- Department of Medical Parasitology and Mycology, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
| | - Kourosh Cheraghipour
- Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
| | - Abdolrazagh Marzban
- Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
| |
Collapse
|
8
|
MicroRNA-4287 is a novel tumor suppressor microRNA controlling epithelial-to mesenchymal transition in prostate cancer. Oncotarget 2020; 11:4681-4692. [PMID: 33473254 PMCID: PMC7771715 DOI: 10.18632/oncotarget.27849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2020] [Accepted: 12/08/2020] [Indexed: 11/25/2022] Open
Abstract
Prostate cancer (PCa) is a significant cause of male morbidity in the United States. Despite recent advances in diagnosis and therapeutic interventions, significant fraction of cases still progress to an advanced stage. Various genetic/epigenetic elements that facilitate this progression are not yet completely known and the mechanism that favors advanced disease is an area of investigation. A characteristic feature associated with progressive disease is deletion of chromosome 8p (chr8p) region, that harbors tumor-suppressor NKX3.1. Previous studies from our group has shown that there are cluster of microRNAs (miRNAs) located within this region whose loss favors advanced, metastatic disease. miR-4287 is a novel miRNA located within this region that has not been studied before. In the present study, we analyzed the role of miR-4287 in PCa using clinical tissues and cell lines. We observed that miR-4287 is significantly downregulated in patient-derived tumor tissues. Receiver operating curve (ROC) analysis showed that miR-4287 distinguishes prostate cancer from normal with a specificity of 88.24% and with an Area under the curve (AUC) of 0.66. Further, we found that miR-4287 levels correlate inversely with patients' serum prostate-specific antigen levels. Ectopic over-expression of miR-4287 in PCa cell lines showed that miR-4287 plays a tumor suppressor role. miR-4287 led to an increase in G2/M phase of cell cycle in PCa cell lines. Further, ectopic miR-4287 inhibited PCa epithelial-to-mesenchymal transition (EMT) by directly repressing SLUG and stem cell marker CD44. Since miR-4287 specifically targets metastasis pathway mediators, miR-4287 has potential diagnostic and therapeutic significance in preventing advanced, metastatic disease.
Collapse
|
9
|
Lu K, Yu M, Chen Y. Non-coding RNAs regulating androgen receptor signaling pathways in prostate cancer. Clin Chim Acta 2020; 513:57-63. [PMID: 33309734 DOI: 10.1016/j.cca.2020.11.027] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Revised: 11/24/2020] [Accepted: 11/30/2020] [Indexed: 12/24/2022]
Abstract
Prostate cancer (PCa) is one of the most common malignancies for men worldwide, and abnormal activation of the androgen receptor (AR) signaling plays an important role in the progression of PCa. However, in the androgen deprivation therapy (ADT), AR signaling inevitably recovered, as a result, exploring novel regulating mechanisms is of great importance. Recently, non-coding RNAs (ncRNAs), including microRNAs, long non-coding RNAs, circular RNAs, could be involved in the progression of PCa, and participate in the regulatory network of AR signaling in a variety of ways. This will help to identify novel molecular mechanisms to promote the development of PCa and find new potential therapeutic targets. In this review, we provide a synopsis of the latest research relating to ncRNAs and associated AR signaling in PCa.
Collapse
Affiliation(s)
- Ke Lu
- Department of Urology, Changshu Second People's Hospital, Yangzhou University Fifth Clinical Medical College, Changshu, China
| | - Muyuan Yu
- Department of Urology, Changshu Second People's Hospital, Yangzhou University Fifth Clinical Medical College, Changshu, China
| | - Yongchang Chen
- Department of Urology, Changshu Second People's Hospital, Yangzhou University Fifth Clinical Medical College, Changshu, China.
| |
Collapse
|
10
|
Huang H, Qing XY, Zhou Q, Li HD, Hu ZY. Silencing of microRNA-3175 represses cell proliferation and invasion in prostate cancer by targeting the potential tumor-suppressor SCN4B. Kaohsiung J Med Sci 2020; 37:20-26. [PMID: 32833340 DOI: 10.1002/kjm2.12292] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2020] [Revised: 05/19/2020] [Accepted: 07/19/2020] [Indexed: 12/24/2022] Open
Abstract
MicroRNA-3175 (miR-3175) expression is upregulated in prostate cancer, but its roles and the underlying mechanisms in prostate cancer cell growth and invasion need to be elucidated. This study aimed to uncover the roles of miR-3175 in regulating cell growth and migration, as well as the expression of its predicted target gene cardiac sodium channel β4-subunit gene (SCN4B). Real-time quantitative PCR (RT-qPCR) and/or western blotting techniques were used to measure miR-3175 and SCN4B expression levels in prostate cancer cells. Inhibitor or mimics transfections were used to overexpress or silence miR-3175 in prostate cancer cells. MTT and Edu assays were applied to assess cell viability. Scratch assay and transwell chambers were used to examine cell migration and invasion abilities. The interaction between miR-3175 and SCN4B was determined by means of luciferase gene reporter, RT-qPCR, and western blotting assays. The results showed that miR-3175 expression was increased and SCN4B expression was decreased in prostate cancer cell lines as compared with normal human prostatic epithelial cells. Compared with the control group, knockdown of miR-3175 resulted in strong inhibitions of cell growth, migration, invasion, and N-cadherin expression, together with an increase in E-cadherin expression. In addition, knockdown of miR-3175 dramatically increased the luciferase activity of the luciferase vector of SCN4B, and increased SCN4B expression. Together, this study illustrated that downregulation of miR-3175 repressed the proliferation and invasion of prostate cancer cells, which might be induced by SCN4B downregulation.
Collapse
Affiliation(s)
- He Huang
- Department of Anesthesiology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - Xiao-Yan Qing
- Department of Oncology, Chengdu Seventh People's Hospital, Chengdu, China
| | - Qiong Zhou
- Department of Medical, the Third Hospital of Nanchang, Nanchang, China
| | - Han-Dan Li
- Department of Anesthesiology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - Zhu-Yun Hu
- Department of Urology, the Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, China
| |
Collapse
|
11
|
Dysregulated Transcriptional Control in Prostate Cancer. Int J Mol Sci 2019; 20:ijms20122883. [PMID: 31200487 PMCID: PMC6627928 DOI: 10.3390/ijms20122883] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2019] [Revised: 06/06/2019] [Accepted: 06/07/2019] [Indexed: 12/24/2022] Open
Abstract
Recent advances in whole-genome and transcriptome sequencing of prostate cancer at different stages indicate that a large number of mutations found in tumors are present in non-protein coding regions of the genome and lead to dysregulated gene expression. Single nucleotide variations and small mutations affecting the recruitment of transcription factor complexes to DNA regulatory elements are observed in an increasing number of cases. Genomic rearrangements may position coding regions under the novel control of regulatory elements, as exemplified by the TMPRSS2-ERG fusion and the amplified enhancer identified upstream of the androgen receptor (AR) gene. Super-enhancers are increasingly found to play important roles in aberrant oncogenic transcription. Several players involved in these processes are currently being evaluated as drug targets and may represent new vulnerabilities that can be exploited for prostate cancer treatment. They include factors involved in enhancer and super-enhancer function such as bromodomain proteins and cyclin-dependent kinases. In addition, non-coding RNAs with an important gene regulatory role are being explored. The rapid progress made in understanding the influence of the non-coding part of the genome and of transcription dysregulation in prostate cancer could pave the way for the identification of novel treatment paradigms for the benefit of patients.
Collapse
|